Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
1.
Oncogene ; 35(47): 6077-6086, 2016 11 24.
Article in English | MEDLINE | ID: mdl-27157619

ABSTRACT

Notch receptors have been implicated as oncogenic drivers in several cancers, the most notable example being NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL). To characterize the role of activated NOTCH3 in cancer, we generated an antibody that detects the neo-epitope created upon gamma-secretase cleavage of NOTCH3 to release its intracellular domain (ICD3), and sequenced the negative regulatory region (NRR) and PEST (proline, glutamate, serine, threonine) domain coding regions of NOTCH3 in a panel of cell lines. We also characterize NOTCH3 tumor-associated mutations that result in activation of signaling and report new inhibitory antibodies. We determined the structural basis for receptor inhibition by obtaining the first co-crystal structure of a NOTCH3 antibody with the NRR protein and defined two distinct epitopes for NRR antibodies. The antibodies exhibit potent anti-leukemic activity in cell lines and tumor xenografts harboring NOTCH3 activating mutations. Screening of primary T-ALL samples reveals that 2 of 40 tumors examined show active NOTCH3 signaling. We also identified evidence of NOTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, 2 of which exhibit activation of NOTCH3 without activation of NOTCH1. Our studies provide additional insights into NOTCH3 activation and offer a path forward for identification of cancers that are likely to respond to therapy with NOTCH3 selective inhibitory antibodies.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , Mutation , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics , Receptor, Notch3/antagonists & inhibitors , Receptor, Notch3/genetics , Amino Acid Substitution , Animals , Cell Line, Tumor , Codon , Disease Models, Animal , Epitopes/chemistry , Epitopes/immunology , Female , Humans , Mice , Models, Molecular , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Protein Conformation , Receptor, Notch3/chemistry , Receptor, Notch3/metabolism , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
2.
Environ Pollut ; 131(1): 81-91, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15210278

ABSTRACT

Leaching of three pesticides (isoproturon, chlorotoluron and triasulfuron) and a tracer (bromide) were determined in four contrasting soils ranging in texture from sandy loam to clay. The compounds were applied to undisturbed columns of soil and four columns for each soil were randomly selected and leached with 24-mm equivalent of water at prescribed time intervals (3, 9, 24, 37 and 57 d after application). A rapid decline in leached loads of isoproturon and chlorotoluron as time from application to irrigation increased was observed in all soils. In contrast, triasulfuron and bromide loads only decreased rapidly in the clay soil. Bromide losses decreased with decreasing clay contents of the soil and therefore with a decrease in structural development. Magnitudes of pesticide losses varied from soil to soil, depending on structural development and the organic carbon content. Pesticide degradation experiments on disturbed and undisturbed soil samples showed that the rapid decline of leached loads with time was faster than could be explained by degradation alone. Five physico-chemical processes are put forward to explain the different patterns of pesticide leached loads observed in the soils: (1) relative extent of preferential flow, (2) sorption capacity of the compounds to the different soils, (3) extent of degradation of the compounds in the soil, (4) variation in sorption kinetics between compounds associated with pesticide diffusion into soil aggregates, and (5) protection of the compounds by a combination of intra-aggregate diffusion and the presence of preferential flow pathways.


Subject(s)
Environmental Monitoring/methods , Herbicides/analysis , Pesticide Residues/analysis , Soil Pollutants/analysis , Soil/analysis , Diffusion , Models, Theoretical
3.
Genes Dev ; 15(24): 3342-54, 2001 Dec 15.
Article in English | MEDLINE | ID: mdl-11751639

ABSTRACT

Transcriptional activation of Wnt/Wg-responsive genes requires the stabilization and nuclear accumulation of beta-catenin, a dedicated coactivator of LEF/TCF enhancer-binding proteins. Here we report that recombinant beta-catenin strongly enhances binding and transactivation by LEF-1 on chromatin templates in vitro. Interestingly, different LEF-1 isoforms vary in their ability to bind nucleosomal templates in the absence of beta-catenin, owing to N-terminal residues that repress binding to chromatin, but not nonchromatin, templates. Transcriptional activation in vitro requires both the armadillo (ARM) repeats and the C terminus of beta-catenin, whereas the phosphorylated N terminus is inhibitory to transcription. A fragment spanning the C terminus (CT) and ARM repeats 11 and 12 (CT-ARM), but not the CT alone, functions as a dominant negative inhibitor of LEF-1-beta-cat activity in vitro and can block ATP-dependent binding of the complex to chromatin. LEF-1-beta-cat transactivation in vitro was also repressed by inhibitor of beta-catenin and Tcf-4 (ICAT), a physiological inhibitor of Wnt/Wg signaling that interacts with ARM repeats 11 and 12, and by the nonsteroidal anti-inflammatory compound, sulindac. None of these transcription inhibitors (CT-ARM, ICAT, or sulindac) could disrupt the LEF-1-beta-cat complex after it was stably bound to chromatin. We conclude that the CT-ARM region of beta-catenin functions as a chromatin-specific activation domain, and that several inhibitors of the Wnt/Wg pathway directly modulate LEF-1-beta-cat activity on chromatin.


Subject(s)
Chromatin/metabolism , Cytoskeletal Proteins/metabolism , DNA-Binding Proteins/metabolism , Transcription Factors/metabolism , Zebrafish Proteins , Amino Acid Sequence , Animals , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Binding Sites , Cell Nucleus/metabolism , Chromatin/genetics , DNA-Binding Proteins/antagonists & inhibitors , DNA-Binding Proteins/genetics , Drosophila , Humans , Lymphoid Enhancer-Binding Factor 1 , Molecular Sequence Data , Mutation , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Sequence Homology, Amino Acid , Signal Transduction , Sulindac/pharmacology , TCF Transcription Factors , Trans-Activators/metabolism , Transcription Factor 7-Like 2 Protein , Transcription Factors/antagonists & inhibitors , Transcription Factors/genetics , Transcription, Genetic , Transcriptional Activation , Wnt Proteins , beta Catenin
4.
Methods Mol Biol ; 176: 283-96, 2001.
Article in English | MEDLINE | ID: mdl-11554329

ABSTRACT

The authors have described three approaches for analyzing the chromatin architecture of a steroid-responsive promoter. Mnase allows one to map the positions of nucleosomes on the target gene. The more sensitive restriction enzyme hypersensitivity procedure permits detection of changes in chromatin architecture upon hormonal stimulation. Additional insight into transcriptional regulation of a gene can be obtained by using the related ExoIII footprinting protocol, which provides complementary data on transcription factor binding to chromatin templates. The use of these in vivo chromatin analysis techniques have provided evidence for a role of chromatin structure in regulation of transcription of steroid-responsive promoters including MMTV (2,7,10,14), tyrosine aminotransferase (15), TR beta A (16-19), and retinoic acid receptor beta (RAR beta) (20).


Subject(s)
Chromatin/physiology , Mammary Tumor Virus, Mouse/genetics , Nucleic Acid Conformation , Promoter Regions, Genetic , Receptors, Steroid/metabolism , Transcriptional Activation , Animals , Humans
6.
Pest Manag Sci ; 57(12): 1127-34, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11802600

ABSTRACT

Twelve lysimeters with a surface area of 0.5 m2 and a length of 60 cm were taken over mole drains from a Denchworth heavy clay soil and divided into two groups with either a standard agricultural tilth or a finer topsoil tilth. The influence of topsoil tilth on leaching of the herbicide isoproturon and a bromide tracer was evaluated over a winter season. The effect of variations in soil moisture status in the immediate topsoil on leaching of isoproturon, chlorotoluron and linuron was investigated in the following winter season. Here, water inputs were controlled such that lysimeters received 50 mm at a maximum intensity of 2 mm h-1 over a 4-week period with herbicides applied on day 15. Three treatments received the water either all prior to application, all after application, or evenly spread over the 4-week period. Leaching losses of the three herbicides were monitored for a subsequently drainage event. Analysis of covariance showed a significant effect of topsoil tilth and total flow on both the maximum concentrations (P = 0.034) and total losses (P = 0.012) of isoproturon in drainflow. Both concentrations and losses were c 35% smaller from lysimeters with the finer tilth. However, generation of the fine tilth in the field was restricted by a wet autumn and this is not considered a reliable management option for reducing pesticide losses from heavy clay soils. In the second experiment, variation in soil moisture content prior to and after application did not have any significant effect (P < 0.05) upon subsequent losses of the three herbicides to drains.


Subject(s)
Bromides/metabolism , Herbicides/metabolism , Pesticide Residues/metabolism , Soil Pollutants/metabolism , Water Pollutants, Chemical/metabolism , Water/metabolism , Aluminum Silicates/analysis , Clay , Hydrogen-Ion Concentration , Linuron/metabolism , Methylurea Compounds/metabolism , Particle Size , Phenylurea Compounds/metabolism , Seasons , Soil/analysis , Time Factors , Water/administration & dosage
7.
Med Pediatr Oncol ; 35(1): 41-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10881006

ABSTRACT

BACKGROUND: A relationship between young age and increased risk of recurrence of pediatric differentiated thyroid carcinoma has been suggested; however, no attempts have been made to assess the prognostic factors or efficacy of treatment in very young children with this malignancy. The objectives of this study were to evaluate the association of age with outcome in pediatric differentiated thyroid carcinoma and to compare the clinical, pathologic, prognostic, and treatment variables between younger and older children with this disease. PROCEDURE: A retrospective review of all patients presenting to the British Columbia's Children's Hospital or British Columbia Cancer Agency <17 years of age at diagnosis with differentiated thyroid carcinoma between January, 1955, and December, 1996, was completed. RESULTS: Thirty-eight patients were identified, 12 of whom were 10 years. An association between young age and extrathyroidal tumor invasion was identified (P = 0.016); however, the latter factor did not independently predict outcome. There was a trend for suppressive doses of thyroid hormone to improve outcome, particularly with increasing age at diagnosis, but this was not statistically significant. CONCLUSIONS: Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. The results suggest different tumor biology in young children requiring novel approaches to therapy to decrease recurrence rates.


Subject(s)
Adenocarcinoma, Follicular/mortality , Adenocarcinoma, Follicular/secondary , Carcinoma, Papillary/mortality , Carcinoma, Papillary/secondary , Thyroid Neoplasms/mortality , Thyroid Neoplasms/pathology , Adolescent , Age Factors , Child , Child, Preschool , Disease-Free Survival , Female , Humans , Lung Neoplasms/secondary , Lymphatic Metastasis , Male , Medical Records , Multivariate Analysis , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Registries , Retrospective Studies , Survival Analysis , Time Factors
8.
J Thorac Cardiovasc Surg ; 119(6): 1154-61, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10838532

ABSTRACT

OBJECTIVE: We sought to establish the outcome and optimal therapeutic sequence for patients with nonmetastatic Ewing sarcoma/primitive neuroectodermal tumor of the chest wall. METHODS: Patients 30 years of age or younger with nonmetastatic Ewing sarcoma/primitive neuroectodermal tumor of the bone were randomly assigned to receive vincristine, doxorubicin, cyclophosphamide, and dactinomycin or those drugs alternating with ifosfamide and etoposide. Local control was obtained with an operation, radiotherapy, or both. RESULTS: Fifty-three (13.4%) of 393 patients had primary tumors of the chest wall (all rib). Event-free survival at 5 years was 57% for the chest wall compared with 61% for other sites (P >.2). Ifosfamide and etoposide improved outcome in the overall group (5-year event-free survival, 68% vs 54%; P =.002), and a similar trend occurred in chest wall lesions (5-year event-free survival, 64% vs 51%). Patients with chest wall lesions had more attempts at initial surgical resection (30%) than those with other primary tumor sites (8%, P <.01). The attempt at initial resection for chest wall lesions did not correlate with size. Initial resections at other sites were restricted to smaller tumors. Initial resection resulted in negative pathologic margins in 6 of 16 patients, whereas the delayed resection resulted in negative margins in 17 of 24 patients (P =.05). Although there was no difference in survival by timing of the operation in rib lesions, a higher percentage of patients with initial surgical resection received radiation than those with resection after initial chemotherapy (P =. 13). CONCLUSIONS: Although rib primary tumors are significantly larger than tumors found in other sites, their outcome is similar. We favor delayed resection whenever possible to minimize the number of patients requiring radiation therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/surgery , Ribs , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/surgery , Adolescent , Adult , Bone Neoplasms/mortality , Child , Combined Modality Therapy , Disease-Free Survival , Humans , Sarcoma, Ewing/mortality , Treatment Outcome
9.
J Biol Chem ; 275(26): 20061-8, 2000 Jun 30.
Article in English | MEDLINE | ID: mdl-10751396

ABSTRACT

Steroid receptors represent a class of transcription regulators that act in part by overcoming the often repressive nature of chromatin to modulate gene activity. The mouse mammary tumor virus (MMTV) promoter is a useful model for studying transcriptional regulation by steroid hormone receptors in the context of chromatin. The chromatin architecture of the promoter prevents the assembly of basal transcription machinery and binding of ubiquitous transcription factors. However, in human breast carcinoma T47D cells lacking the glucocorticoid receptor (GR), but expressing the progesterone receptor (PR), nucleosome B (nuc B) assumes a constitutively hypersensitive chromatin structure. This correlation led us to test the hypothesis that the chromatin structure of nuc B was dependent on GR expression in T47D cells. To examine this possibility, we stably co-transfected the MMTV promoter and the GR into T47D cells that lacked both the GR and the PR. We found that in T47D cells that lack both the GR and the PR or express only the GR, nuc B assumes a constitutively "open" chromatin structure, which allows hormone independent access by restriction endonucleases and transcription factors. These results suggest that in GR(+)/pr(-) T47D cells, the MMTV chromatin structure permits GR transcriptional activation, independent of chromatin remodeling.


Subject(s)
Breast Neoplasms/virology , CCAAT-Enhancer-Binding Proteins , Chromatin/metabolism , Mammary Tumor Virus, Mouse/genetics , Promoter Regions, Genetic , Receptors, Glucocorticoid/metabolism , Transcription Factors , Blotting, Western , Cell Nucleus/metabolism , Chromatin/chemistry , DNA-Binding Proteins/metabolism , Dexamethasone/pharmacology , Glucocorticoids/pharmacology , Humans , Hypersensitivity , NFI Transcription Factors , Nuclear Proteins , Precipitin Tests , Protein Binding , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic , Transfection , Tumor Cells, Cultured , Y-Box-Binding Protein 1
10.
J Biol Chem ; 275(23): 17771-7, 2000 Jun 09.
Article in English | MEDLINE | ID: mdl-10748103

ABSTRACT

Steroid hormones regulate the transcription of numerous genes via high affinity receptors that act in concert with chromatin remodeling complexes, coactivators and corepressors. We have compared the activities of a variety of glucocorticoid receptor (GR) antagonists in breast cancer and osteosarcoma cell lines engineered to stably maintain the mouse mammary tumor virus promoter. In both cell types, GR activation by dexamethasone occurs via the disruption of mouse mammary tumor virus chromatin structure and the recruitment of receptor coactivator proteins. However, when challenged with a variety of antagonists the GR displays differential ability to activate transcription within the two cell types. For the breast cancer cells, the antagonists fail to activate the promoter and do not promote the association of the GR with either remodeling or coactivator proteins. In contrast, in osteosarcoma cells, the antiglucocorticoids, RU486 and RU43044, exhibit partial agonist activity. The capacity of these antagonists to stimulate transcription in the osteosarcoma cells is reflected in the ability of the RU486-bound receptor to remodel chromatin and associate with chromatin-remodeling proteins. Similarly, the observation that the RU486-bound receptor does not fully activate transcription is consistent with its inability to recruit receptor coactivator proteins.


Subject(s)
Dexamethasone/pharmacology , Gene Expression Regulation, Neoplastic , Glucocorticoids/pharmacology , Hormone Antagonists/pharmacology , Hydroxycorticosteroids , Mammary Tumor Virus, Mouse/genetics , Mifepristone/pharmacology , Receptors, Glucocorticoid/metabolism , Animals , Breast Neoplasms , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Mice , Osteosarcoma , Promoter Regions, Genetic , Receptors, Glucocorticoid/drug effects , Transcription, Genetic/drug effects , Tumor Cells, Cultured
11.
Int J Radiat Oncol Biol Phys ; 43(1): 47-55, 1999 Jan 01.
Article in English | MEDLINE | ID: mdl-9989513

ABSTRACT

PURPOSE: To compare the efficacy of pion radiation therapy with conventional external beam photon therapy, for the treatment of locally advanced stage T3/4, N0, M0 adenocarcinoma of the prostate. METHODS AND MATERIALS: Two hundred seventeen eligible patients were randomly allocated to either photon or pion therapy. No adjuvant hormone therapy was used. RESULTS: Median follow-up was 42 months (range 2-90). Acute bladder toxicity was worse in the pion arm, p = 0.2, but other acute toxicity did not differ. Late grade 2 toxicity was significantly less in the pion arm (29% at 5 years versus 48%, p = 0.002), but late grade 3 or 4 toxicity did not differ. Clinical local control was not significantly different between treatment arms (64% after 5 years with photons, 56% with pions, p = 0.6). Cause-specific and overall survival also did not differ (p = 0.7). There was a significant delay in time to first failure in the photon arm, largely as a result of decreased biochemical relapse, p = 0.01. A multivariate analysis is presented. CONCLUSION: Pion therapy was well tolerated, with increased acute toxicity and significantly decreased late tissue injury. This contrasts with the late toxicity observed with higher LET particle therapy such as neutron therapy. No improvement in local control with pion therapy was observed.


Subject(s)
Adenocarcinoma/radiotherapy , Mesons/therapeutic use , Photons/therapeutic use , Prostatic Neoplasms/radiotherapy , Radiotherapy, Conformal/methods , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Aged , Aged, 80 and over , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Staging , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Quality of Life , Radiotherapy Dosage
12.
Nature ; 393(6680): 88-91, 1998 May 07.
Article in English | MEDLINE | ID: mdl-9590696

ABSTRACT

The assembly of transcriptional regulatory DNA sequences into chromatin plays a fundamental role in modulating gene expression. The promoter of the mouse mammary-tumour virus (MMTV) is packaged into a regular array of nucleosomes when it becomes stably integrated into mammalian chromosomes, and has been used to investigate the relationship between chromatin architecture and transcriptional activation by the hormone-bound glucocorticoid and progesterone receptors. In mammalian cells that express both of these receptors, the progesterone receptor activates transcription from transiently transfected MMTV DNA but not from organized chromatin templates. Moreover, the activated progesterone receptor inhibits the chromatin remodelling and consequent transcriptional stimulation that is mediated by the glucocorticoid receptor. Here we investigate the mechanism of this inhibition by characterizing the interaction of the glucocorticoid receptor with transcriptional co-activator and chromatin remodelling protein complexes. We show that when this receptor is prevented from interacting with the hBRG1/BAF chromatin remodelling complex, it can activate transcription from transiently transfected DNA but not from organized chromatin templates. Our results indicate that it may be possible to separate the transcriptional activation and chromatin remodelling activities of proteins that interact with hormone receptors.


Subject(s)
Chromatin/physiology , Nuclear Proteins/physiology , Receptors, Glucocorticoid/physiology , Trans-Activators , Transcription Factors/physiology , Animals , DNA Helicases , Estrenes/pharmacology , Furans/pharmacology , Gene Expression Regulation , Hormone Antagonists/pharmacology , Mammary Tumor Virus, Mouse/genetics , Mammary Tumor Virus, Mouse/physiology , Nuclear Proteins/metabolism , Receptors, Glucocorticoid/antagonists & inhibitors , Receptors, Progesterone/antagonists & inhibitors , Receptors, Progesterone/physiology , Transcription Factors/metabolism , Transcriptional Activation , Tumor Cells, Cultured
13.
J Clin Oncol ; 16(3): 897-906, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9508171

ABSTRACT

PURPOSE: A randomized trial designed to compare mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)/doxorubicin, bleomycin, vinblastine, and daccarbazine (ABVD) (regimen A) with ABVD plus low-dose regional (extended-field) radiation therapy (EF RT) (regimen B) for the treatment of children and adolescents with stages III and IV Hodgkin's disease was conducted by the Children's Cancer Group (CCG-521) from 1986 until 1990. PATIENTS AND METHODS: One hundred eleven eligible patients were randomized, 57 to regimen A and 54 to regimen B. All patients had pathologically verified stage III or stage IV Hodgkin's disease. RESULTS: Overall survival (S) is 87% at 4 years and event-free survival (EFS) is 82%. Patients randomized to ABVD plus EF RT have a 4-year EFS of 87% compared with 77% for patients randomized to MOPP/ABVD (P = .09, two-sided). Patients randomized to ABVD plus EF RT have a 4-year S of 90% compared with 84% for patients randomized to MOPP/ABVD (P = .45, two-sided). Significant prognostic factors in multivariate analysis for EFS are stage of disease, erythrocyte sedimentation rate (ESR) at diagnosis, liver size at diagnosis, and, among stage III patients, the size of the mediastinal mass at diagnosis. The acute toxicities of treatment are largely hematopoietic in nature, whereas acute pulmonary and cardiac toxicities are modest and not limiting. CONCLUSION: The results of this study show that, in advanced-stage Hodgkin's disease in children, equivalent results can be obtained by the addition of either MOPP or low-dose EF RT to the ABVD regimen; whether the addition of either contributes to outcome was not addressed in this study and will require additional testing. It is clear, however, that MOPP chemotherapy can safely be eliminated from front-line combination chemotherapy regimens for advanced Hodgkin's disease in pediatric patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Adolescent , Bleomycin/administration & dosage , Child , Combined Modality Therapy , Dacarbazine/administration & dosage , Doxorubicin/administration & dosage , Female , Hodgkin Disease/pathology , Hodgkin Disease/radiotherapy , Humans , Male , Mechlorethamine/administration & dosage , Multivariate Analysis , Neoplasm Staging , Prednisone/administration & dosage , Procarbazine/administration & dosage , Prognosis , Proportional Hazards Models , Survival Analysis , Vinblastine/administration & dosage , Vincristine/administration & dosage
14.
J Biol Chem ; 273(2): 1175-83, 1998 Jan 09.
Article in English | MEDLINE | ID: mdl-9422784

ABSTRACT

We examined the mechanism(s) by which the progesterone receptor (PR) is able to inhibit glucocorticoid receptor (GR) activation from the mouse mammary tumor virus (MMTV) promoter in vivo. Using specific hormone antagonists, we demonstrate that the PR complexed with an type II antiprogestin blocks glucocorticoid-induced activation of the MMTV promoter. However, when complexed with a type I antiprogestin the PR is unable to block glucocorticoid-induced activation. PR repression of GR activity results from the inhibition of the ability of the GR to remodel chromatin such that the antiprogestin-occupied/PR prevents the glucocorticoid induced assembly of a preinitiation complex at MMTV promoter. These experiments suggest that the specific chromatin organization of the MMTV promoter provides a mechanism for regulating cross-talk between the GR and PR in vivo.


Subject(s)
Chromatin/chemistry , Hormone Antagonists/pharmacology , Progesterone/antagonists & inhibitors , Receptors, Glucocorticoid/drug effects , Dexamethasone/pharmacology , Humans , Mammary Tumor Virus, Mouse/genetics , Models, Molecular , Protein Conformation , Receptors, Glucocorticoid/physiology , Transcription, Genetic/drug effects , Transcription, Genetic/physiology , Tumor Cells, Cultured
15.
Med Pediatr Oncol ; 29(4): 308-12, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9251739

ABSTRACT

Primitive neuroectodermal tumours (PNET) of the ovary are rare, aggressive tumours which are associated with high morbidity and mortality. Previously reported cases have shown limited response to therapy in patients presenting with metastatic disease and survival rates have been discouragingly low. We report the case of a 13-year-old girl who presented with a primary ovarian PNET and extensive metastatic disease. Pathologic studies confirmed the neural origin of the tumour and its morphologic appearance of neuroblastoma. Incomplete surgical resection was followed by treatment with aggressive multi-agent chemotherapy including cis-platinum, etoposide, cyclophosphamide, anddoxorubicin as per a neuroblastoma treatment protocol. Complete clinical remission ensued and she received consolidative therapy with myeloablative doses of thiotepa, melphalan, and carboplatin followed by autologous peripheral blood progenitor cell rescue. All therapy was well tolerated and the patient remains in complete remission with no evidence of disease 18 months from presentation. Mega-dose chemotherapy followed by progenitor cell rescue may provide optimal therapy for patients presenting with metastatic ovarian PNET.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation , Neuroectodermal Tumors, Primitive/therapy , Ovarian Neoplasms/therapy , Adolescent , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Humans , Neuroectodermal Tumors, Primitive/secondary
16.
Methods ; 12(1): 105-14, 1997 May.
Article in English | MEDLINE | ID: mdl-9169200

ABSTRACT

A number of important nuclear processes including replication, recombination, repair, and transcription involve the interaction of soluble nuclear proteins with DNA assembled as chromatin. Recent progress in a number of experimental systems has focused attention on the influence chromatin structure may exert on gene regulation in eukaryotes. With the advent of new technologies for the analysis of chromatin structure in vivo, studies evaluating the influence of chromatin structure on gene transcription have become feasible for a number of systems. This article serves as an introduction to the use of restriction endonucleases to define nucleosomal organization and characterize changes in this organization that accompany transcriptional activation in vivo. The procedure includes the isolation of intact transcriptionally competent nuclei, limited digestion with specific restriction endonucleases, and purification of the DNA. This DNA serves as the substrate for a linear amplification using single primers that generate enzyme-specific DNA fragments, which are then resolved by electrophoresis. Specific examples related to our studies of the influence of chromatin structure on steroid hormone regulation of transcription from the mouse mammary tumor virus promoter are provided to illustrate this technique and several novel variations. Alternative methods for analysis of chromatin architecture using DNase I, micrococcal nuclease, permanganate, and methidiumpropyl-EDTA-iron(II) are also described. Through the use of these methodologies one is able to determine both the translational and the rotational positions for a given nucleosome as well as quantify changes at a specific nucleosome in response to regulatory and developmental signals.


Subject(s)
Chromatin/chemistry , DNA Restriction Enzymes/metabolism , Nucleosomes/chemistry , Transcription, Genetic , Animals , Cell Nucleus/chemistry , Cell Nucleus/metabolism , Cells, Cultured , Chromatin/metabolism , DNA/isolation & purification , DNA/metabolism , Deoxyribonuclease I/metabolism , Deoxyribonucleases, Type II Site-Specific/metabolism , Edetic Acid/analogs & derivatives , Edetic Acid/metabolism , Electrophoresis, Polyacrylamide Gel , Genes, Reporter , Mammary Tumor Virus, Mouse/genetics , Micrococcal Nuclease/metabolism , Nucleosomes/metabolism , Potassium Permanganate , Promoter Regions, Genetic/genetics , Transcriptional Activation , Transfection/genetics
17.
J Pediatr Hematol Oncol ; 19(2): 115-23, 1997.
Article in English | MEDLINE | ID: mdl-9149740

ABSTRACT

PURPOSE: Currently bone marrow transplantation (BMT) with an HLA-identical sibling donor is recommended as optimal therapy for children with acquired severe aplastic anemia (SAA). Immunosuppressive therapy (IST) has become a very successful initial therapy for SAA in children lacking a related bone marrow donor. We wished to evaluate whether current IST regimens may be as efficacious as BMT. PATIENTS AND METHODS: A retrospective review identified children treated for SAA over a 12-year period. Children with a related donor received a BMT. Children lacking a donor were treated with IST followed by a "rescue" BMT if IST was ineffective. IST consisted of anti-thymocyte globulin and steroid +/- cyclosporine A. Transfusion independence and survival rates were compared between the two groups. RESULTS: Twenty-seven children were identified. Nine received a related BMT; seven of these survive and are transfusion independent (median follow-up 54 months). Sixteen of 18 patients who received IST are transfusion-independent survivors, including three of four patients who received a rescue BMT (median follow-up 33.5 months). Actuarial survival is 75% (95% CI = 45%, 105%) and 92% (95% CI = 78%, 107%) for the BMT and IST groups, respectively (p = 0.15). Severe toxicity was not experienced by any patient as a result of IST. CONCLUSIONS: Equivalent rates of transfusion independence and survival were experienced by patients receiving BMT and IST. We propose that a prospective trial be undertaken to evaluate IST as initial therapy in all children with SAA, to be followed by BMT if there is inadequate response.


Subject(s)
Anemia, Aplastic/therapy , Bone Marrow Transplantation , Immunosuppressive Agents/therapeutic use , Adolescent , Bone Marrow Transplantation/adverse effects , British Columbia , Child , Child, Preschool , Humans , Immunosuppressive Agents/adverse effects , Infant , Retrospective Studies , Survival Analysis , Treatment Outcome
18.
Int J Radiat Oncol Biol Phys ; 37(3): 491-7, 1997 Feb 01.
Article in English | MEDLINE | ID: mdl-9112443

ABSTRACT

PURPOSE: This study attempted to compare within a randomized study the outcome of pion radiation therapy vs. conventional photon irradiation for the treatment of high-grade astrocytomas. METHODS AND MATERIALS: Eighty-four patients were randomized to pion therapy (33-34.5 Gy pi), or conventional photon irradiation (60 Gy). Entry criteria included astrocytoma (modified Kernohan high Grade 3 or Grade 4), age 18-70, Karnofsky performance status (KPS) > or = 50, ability to start irradiation within 30 days of surgery, unifocal tumor, and treatment volume < 850 cc. The high-dose volume in both arms was computed tomography enhancement plus a 2-cm margin. The study was designed with the power to detect a twofold difference between arms. RESULTS: Eighty-one eligible patients were equally balanced for all known prognostic variables. Pion patients started radiation 7 days earlier on average than photon patients, but other treatment-related variables did not differ. There were no significant differences for either early or late radiation toxicity between treatment arms. Actuarial survival analysis shows no differences in terms of time to local recurrence or overall survival where median survival was 10 months in both arms (p = 0.22). The physician-assessed KPS and patient-assessed quality of life (QOL) measurements were generally maintained within 10 percentage points until shortly before tumor recurrence. There was no apparent difference in the serial KPS or QOL scores between treatment arms. CONCLUSION: In contrast to high linear energy transfer (LET) therapy for central nervous system tumors, such as neutron or neon therapy, the safety of pion therapy, which is of intermediate LET, has been reaffirmed. However, this study has demonstrated no therapeutic gain for pion therapy of glioblastoma.


Subject(s)
Brain Neoplasms/radiotherapy , Glioblastoma/radiotherapy , Mesons/therapeutic use , Adult , Aged , Brain Neoplasms/mortality , Cause of Death , Glioblastoma/mortality , Humans , Middle Aged , Multivariate Analysis , Neoplasm Recurrence, Local , Photons/therapeutic use , Quality of Life , Radiotherapy Planning, Computer-Assisted
19.
Trends Endocrinol Metab ; 8(10): 384-90, 1997 Dec.
Article in English | MEDLINE | ID: mdl-18406827

ABSTRACT

Steroid hormone receptors are ligand-activated transcription factors that enhance or repress gene expression. They act by binding to target sites within the promoters of genes assembled as chromatin. Chromatin structure is modified in response to steroid hormones and represents a critical step in steroid receptor signaling. Recent experiments demonstrate that the progesterone and glucocorticoid receptors are differentially influenced by this arrangement of DNA and histones. One of the most important developments in the steroid hormone receptor field has been the identification of coactivators and cointegrators, some of which are histone acetyltransferases. These proteins appear to play an important role in mediating ligand activation of transcription, although their exact role on chromatin templates is undefined.

20.
Br J Cancer Suppl ; 27: S122-5, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8763863

ABSTRACT

Female C57BL/6 mice aged 6-8 weeks with transplanted Lewis lung cancer cells were used to investigate the anti-tumour effects and immune reactions in tumour tissue induced by X-ray and pion irradiation and their modification by schizophyllan (SPG). The effect of SPG on the rate of lung metastasis and the survival time of the mice was also studied using the same tumour system. These studies showed that in this tumour system the "practical' relative biological effectiveness (RBE) of pions was 1.33 in the dose ranges used (3 Gy x 4 = P3; 6 Gy x 4 = P6). SPG increased the suppression of tumour growth associated with moderate doses of radiation: X-rays (4 Gy x 4 = X4) or P3. SPG also decreased the number of lung metastases and prolonged the life span of the mice, these effects being independent of radiation. The addition of SPG to radiation increased both the macrophage infiltration and T-lymphocyte infiltration in the local tumour and the lung nodules. There did not appear to be any major differential effect of SPG on the pion-treated mice compared with those treated with X-rays.


Subject(s)
Adjuvants, Immunologic/pharmacology , Carcinoma, Lewis Lung/radiotherapy , Mesons , Sizofiran/pharmacology , Animals , Carcinoma, Lewis Lung/immunology , Carcinoma, Lewis Lung/pathology , Female , Lung Neoplasms/secondary , Macrophages/drug effects , Mice , Mice, Inbred C57BL , Relative Biological Effectiveness , T-Lymphocytes/drug effects , X-Rays
SELECTION OF CITATIONS
SEARCH DETAIL
...